IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Incyte's radiolabeled INCB161734 mass balance study active, not recruitingOct 16Weekly roundup, 4 itemsINCA33890INCB161734
Incyte registers Phase 2 trial of INCA33890 in MRD-positive colorectal cancerSep 16Trial updateINCA33890Incyte Corporation